MVF – Macquarie rates the stock as Outperform
The Outperform rating and target price of $1.20 are retained.
Read More
Monash Ivf Group Limited
The Monash IVF Group recognises that the success of each business is a result of their team of highly skilled, committed and passionate people focused on achieving the best outcomes for patients.
The Monash IVF Group has a world class internal quality assurance program and competency review system which supplements the reviews performed by the reproductive treatment authority committee (RTAC). We quantitatively and qualitatively monitor and control every aspect of the IVF process to ensure our specialists, nurses and scientists consistently provide the highest quality care and our technology performs at the highest level. These comprehensive measures ensure all patients have the best possible opportunity of achieving their dream of having a family.
The Monash IVF Group pride themselves on a multi-disciplinary team approach consisting of Fertility Specialists, Sonologists, Fertility Nurses, Scientists, Counsellors and Patient Coordinators who work closely with their patients to achieve the best possible chance of success.
Videos
Videos coming soon for Monash Ivf Group Limited.
News
MVF – Morgans rates the stock as Add
The broker retains an Add rating and lowers forecasts in-line with the recent trading update. The target price is reduced to $1.25 from $1.29.
Read More
MVF – Macquarie rates the stock as Outperform
The target price lifts to $1.15 from $1.10. The Outperform rating is maintained.
Read More
MVF – Morgans rates the stock as Add
At the AGM, Monash IVF noted a strong rebound from July to October. This was indicated by stimulated cycles growing by 23.1%, international up 16.2% and the Ultrasound business up 10.7%.
Read More
MVF – Morgans rates the stock as Downgrade to Hold from Add
FY20 guidance has been withdrawn. Morgans believes it appropriate to revise forecasts and adjust dividend expectations, as cash conservation is paramount.
Read More
MVF – Morgans rates the stock as Downgrade to Hold from Add
Morgans downgrades Monash IVF to Hold from Add to reflect recent share price strength.
Read More
Not So Fertile Ground For IVF Leader
The flagging housing market and sagging consumer sentiment ahead of the federal and NSW elections have affected the performance of an unlikely ASX-listed exponent - the assisted reproduction outfit Virtus Health (VRT, $3.98).
Read More
